# Part 1, Session 2-F: Consolidated Allowlist Summary

## About This Session

**Context from prior research sessions has been pre-injected above this prompt by the orchestrator.**
The injected context contains the outputs from **all five prior Session 2 sub-sessions**:
- **Session 2-A** — Part-level allowlist for Title 21 (Food and Drugs)
- **Session 2-B** — Part-level allowlist for Title 42 (Public Health)
- **Session 2-C** — Part-level allowlists for Titles 45, 29, 26, 16
- **Session 2-D** — Part-level allowlists for Tier 3 Titles Group 1 (Titles 40, 47, 28, 32, 38)
- **Session 2-E** — Part-level allowlists for Tier 3 Titles Group 2 (Titles 20, 49, 10, 2)

This is a **synthesis session** (2-F within Session 2). Read all five injected outputs to produce the
consolidated deliverables below. Do not search externally for regulatory information — all part-level
data you need is in the injected context.

---

## Cedar Platform Context

Cedar is an AI-powered regulatory intelligence SaaS platform for independent medical practices in
Florida (expanding to all 50 states). Target practice types: Functional Medicine, Hormone Optimization/HRT,
Compounding Pharmacy, Med Spa/Aesthetic Medicine, Weight Management, Peptide Therapy, IV Therapy/Infusion,
Regenerative Medicine, Telehealth, Chiropractic, Integrative Medicine, Anti-Aging Medicine, Pain Management,
and Primary Care (DPC/Concierge).

Cedar has ~99K unclassified entities from eCFR, Federal Register, and openFDA APIs. Session 1 classified
all 50 CFR titles. Sessions 2-A through 2-E drilled down to part-level for all 15 healthcare-relevant
titles. This session consolidates that work into the engineering-ready outputs consumed by Session 8
(CFR-to-domain mapping).

---

## Deliverable 1: Consolidated Summary Table

Using data from Sessions 2-A through 2-E (all injected above), produce:

### Summary Table

| CFR Title | Classification | Total Parts in Title (approx) | Relevant Parts Count | Key Regulatory Areas for Cedar |
| --- | --- | --- | --- | --- |

Include all 50 titles (35 IRRELEVANT + 15 MIXED with part counts).

### Revised Filtering Estimate

Update the Session 1 estimate with part-level precision:

- Total relevant parts across all 15 mixed titles
- Estimated percentage of the 99K entities that survive both title-level AND part-level filtering
- Breakdown by source type:
    - **eCFR entities**: How many survive?
    - **Federal Register entities**: How many survive? (Note: FR documents should also be filterable by issuing agency — FDA, CMS, OSHA, FTC, DEA, OIG documents are retained regardless of title mapping)
    - **openFDA entities**: All presumed relevant (0% elimination from this source)
- Comparison to Session 1's original estimate of ~20,000-29,000 surviving entities

---

## Deliverable 2: Engineering-Ready Allowlist

Produce a flat dictionary suitable for direct implementation in code:

```
RELEVANT_PARTS = {
    "title_21": [11, 50, 54, 56, 201, 202, ...],
    "title_42": [2, 3, 8, 10, 11, 400, 401, ...],
    "title_45": [46, 92, 144, 146, 147, 148, 149, 150, 160, 162, 164, 170, 171, 180, ...],
    ...
}
```

This dictionary will be consumed by the Opus engineering agent to build Cedar's classification pipeline.

Include **every relevant part** from all 15 titles. Do not abbreviate or truncate.

---

## Deliverable 3: Cross-Title Analysis

Produce a brief analysis (1-2 paragraphs per item):

1. **Parts with the highest Cedar relevance** — top 10 most important parts across all titles for Cedar's target practices, with a one-line explanation of why each matters
2. **Parts most likely to generate changes** — which parts are in actively evolving regulatory areas? (e.g., DEA telehealth rules, FDA compounding guidance, CMS telehealth billing)
3. **Gaps or inconsistencies across sessions** — any parts that appear in one session's analysis but not in another's, or any titles where the part-level analysis revealed that Session 1's classification was wrong

---

## Output Guidelines

- This is a synthesis session — do not introduce new part-level analysis. Use only what Sessions 2-A through 2-E produced.
- The engineering-ready allowlist is the most critical output — it must be complete and accurate.
- Produce Deliverable 2 (allowlist) even if individual session outputs have minor gaps — use best available data and note any gaps.
